These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1840 related items for PubMed ID: 23493121

  • 1. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
    Beiderwellen KJ, Poeppel TD, Hartung-Knemeyer V, Buchbender C, Kuehl H, Bockisch A, Lauenstein TC.
    Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors.
    Gaertner FC, Beer AJ, Souvatzoglou M, Eiber M, Fürst S, Ziegler SI, Brohl F, Schwaiger M, Scheidhauer K.
    Invest Radiol; 2013 May; 48(5):263-72. PubMed ID: 23385399
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of 68Ga-DOTATOC PET/MRI for whole-body staging of neuroendocrine tumours in comparison with 68Ga-DOTATOC PET/CT.
    Sawicki LM, Deuschl C, Beiderwellen K, Ruhlmann V, Poeppel TD, Heusch P, Lahner H, Führer D, Bockisch A, Herrmann K, Forsting M, Antoch G, Umutlu L.
    Eur Radiol; 2017 Oct; 27(10):4091-4099. PubMed ID: 28439648
    [Abstract] [Full Text] [Related]

  • 4. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors.
    Frilling A, Sotiropoulos GC, Radtke A, Malago M, Bockisch A, Kuehl H, Li J, Broelsch CE.
    Ann Surg; 2010 Nov; 252(5):850-6. PubMed ID: 21037441
    [Abstract] [Full Text] [Related]

  • 5. Staging of neuroendocrine tumours: comparison of [⁶⁸Ga]DOTATOC multiphase PET/CT and whole-body MRI.
    Schraml C, Schwenzer NF, Sperling O, Aschoff P, Lichy MP, Müller M, Brendle C, Werner MK, Claussen CD, Pfannenberg C.
    Cancer Imaging; 2013 Mar 05; 13(1):63-72. PubMed ID: 23466785
    [Abstract] [Full Text] [Related]

  • 6. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
    Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, Brandau W, Bockisch A, Boy C.
    Recent Results Cancer Res; 2013 Mar 05; 194():353-71. PubMed ID: 22918768
    [Abstract] [Full Text] [Related]

  • 7. 68Ga-DOTATOC PET/CT of neuroendocrine tumors: spotlight on the CT phases of a triple-phase protocol.
    Ruf J, Schiefer J, Furth C, Kosiek O, Kropf S, Heuck F, Denecke T, Pavel M, Pascher A, Wiedenmann B, Amthauer H.
    J Nucl Med; 2011 May 05; 52(5):697-704. PubMed ID: 21498531
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography.
    Armbruster M, Sourbron S, Haug A, Zech CJ, Ingrisch M, Auernhammer CJ, Nikolaou K, Paprottka PM, Rist C, Reiser MF, Sommer WH.
    Invest Radiol; 2014 Jan 05; 49(1):7-14. PubMed ID: 24002080
    [Abstract] [Full Text] [Related]

  • 9. Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor.
    Hope TA, Pampaloni MH, Nakakura E, VanBrocklin H, Slater J, Jivan S, Aparici CM, Yee J, Bergsland E.
    Abdom Imaging; 2015 Aug 05; 40(6):1432-40. PubMed ID: 25820755
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Simultaneous positron emission tomography/magnetic resonance imaging for whole-body staging in patients with recurrent gynecological malignancies of the pelvis: a comparison to whole-body magnetic resonance imaging alone.
    Grueneisen J, Beiderwellen K, Heusch P, Gratz M, Schulze-Hagen A, Heubner M, Kinner S, Forsting M, Lauenstein T, Ruhlmann V, Umutlu L.
    Invest Radiol; 2014 Dec 05; 49(12):808-15. PubMed ID: 25010207
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Impact of Multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors.
    Ruf J, Heuck F, Schiefer J, Denecke T, Elgeti F, Pascher A, Pavel M, Stelter L, Kropf S, Wiedenmann B, Amthauer H.
    Neuroendocrinology; 2010 Dec 05; 91(1):101-9. PubMed ID: 19996582
    [Abstract] [Full Text] [Related]

  • 20. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
    Putzer D, Gabriel M, Henninger B, Kendler D, Uprimny C, Dobrozemsky G, Decristoforo C, Bale RJ, Jaschke W, Virgolini IJ.
    J Nucl Med; 2009 Aug 05; 50(8):1214-21. PubMed ID: 19617343
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 92.